TR199801418T2 - Rekombinant a�� vekt�rleri kar���m�. - Google Patents

Rekombinant a�� vekt�rleri kar���m�.

Info

Publication number
TR199801418T2
TR199801418T2 TR1998/01418T TR9801418T TR199801418T2 TR 199801418 T2 TR199801418 T2 TR 199801418T2 TR 1998/01418 T TR1998/01418 T TR 1998/01418T TR 9801418 T TR9801418 T TR 9801418T TR 199801418 T2 TR199801418 T2 TR 199801418T2
Authority
TR
Turkey
Prior art keywords
weightlifting
kar
recombinant
treatment
viruses
Prior art date
Application number
TR1998/01418T
Other languages
English (en)
Turkish (tr)
Inventor
Hurwitz Julia
Coleclough Christopher
Owens Randall
Slobod Karen
Original Assignee
St.Jude Children's Research Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by St.Jude Children's Research Hospital filed Critical St.Jude Children's Research Hospital
Publication of TR199801418T2 publication Critical patent/TR199801418T2/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus human T-cell leukaemia-lymphoma virus
    • C07K14/155—Lentiviridae, e.g. human immunodeficiency virus [HIV], visna-maedi virus or equine infectious anaemia virus
    • C07K14/16—HIV-1 ; HIV-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24171—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
TR1998/01418T 1996-01-23 1997-01-23 Rekombinant a�� vekt�rleri kar���m�. TR199801418T2 (xx)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/590,288 US5741492A (en) 1996-01-23 1996-01-23 Preparation and use of viral vectors for mixed envelope protein vaccines against human immunodeficiency viruses

Publications (1)

Publication Number Publication Date
TR199801418T2 true TR199801418T2 (xx) 1998-10-21

Family

ID=24361647

Family Applications (1)

Application Number Title Priority Date Filing Date
TR1998/01418T TR199801418T2 (xx) 1996-01-23 1997-01-23 Rekombinant a�� vekt�rleri kar���m�.

Country Status (28)

Country Link
US (3) US5741492A (cg-RX-API-DMAC7.html)
EP (2) EP0876498B1 (cg-RX-API-DMAC7.html)
JP (2) JP2000504326A (cg-RX-API-DMAC7.html)
KR (1) KR100571479B1 (cg-RX-API-DMAC7.html)
CN (1) CN1229501C (cg-RX-API-DMAC7.html)
AP (1) AP1200A (cg-RX-API-DMAC7.html)
AT (1) ATE278790T1 (cg-RX-API-DMAC7.html)
AU (1) AU709174B2 (cg-RX-API-DMAC7.html)
BG (1) BG64711B1 (cg-RX-API-DMAC7.html)
BR (1) BR9707611A (cg-RX-API-DMAC7.html)
CA (1) CA2243570C (cg-RX-API-DMAC7.html)
CZ (1) CZ296575B6 (cg-RX-API-DMAC7.html)
DE (1) DE69731075T2 (cg-RX-API-DMAC7.html)
DK (1) DK0876498T3 (cg-RX-API-DMAC7.html)
EA (1) EA002390B1 (cg-RX-API-DMAC7.html)
ES (1) ES2230596T3 (cg-RX-API-DMAC7.html)
GE (1) GEP20032902B (cg-RX-API-DMAC7.html)
HU (2) HU224344B1 (cg-RX-API-DMAC7.html)
IL (2) IL125497A (cg-RX-API-DMAC7.html)
NO (1) NO322261B1 (cg-RX-API-DMAC7.html)
NZ (1) NZ331024A (cg-RX-API-DMAC7.html)
OA (1) OA10814A (cg-RX-API-DMAC7.html)
PL (1) PL188641B1 (cg-RX-API-DMAC7.html)
PT (1) PT876498E (cg-RX-API-DMAC7.html)
RO (1) RO120268B1 (cg-RX-API-DMAC7.html)
TR (1) TR199801418T2 (cg-RX-API-DMAC7.html)
UA (1) UA73712C2 (cg-RX-API-DMAC7.html)
WO (1) WO1997027311A1 (cg-RX-API-DMAC7.html)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7488485B2 (en) * 2003-09-16 2009-02-10 University Of Kansas Medical Center DNA vaccine compositions and methods of use
GB9711957D0 (en) * 1997-06-09 1997-08-06 Isis Innovation Methods and reagents for vaccination
US20030138454A1 (en) * 1997-06-09 2003-07-24 Oxxon Pharmaccines, Ltd. Vaccination method
US6919318B1 (en) * 1998-04-22 2005-07-19 Chiron Corporation Enhancing immune responses to genetic immunization by using a chemokine
WO1999061049A2 (en) * 1998-05-22 1999-12-02 University Of Massachusetts Medical Center Model for infection by a pathogen using administration of nucleic acids
US6562800B1 (en) * 1998-10-30 2003-05-13 University Of Southern California Use of immunopotentiating sequences for inducing immune response
US6759237B1 (en) 1998-11-05 2004-07-06 The Trustees Of The University Of Pennsylvania Adeno-associated virus serotype 1 nucleic acid sequences, vectors and host cells containing same
WO2000028004A1 (en) 1998-11-10 2000-05-18 The University Of North Carolina At Chapel Hill Virus vectors and methods of making and administering the same
US7935805B1 (en) 1998-12-31 2011-05-03 Novartis Vaccines & Diagnostics, Inc Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof
WO2000039304A2 (en) 1998-12-31 2000-07-06 Chiron Corporation Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
EP1141315B1 (en) 1998-12-31 2008-01-23 Novartis Vaccines and Diagnostics, Inc. Modified hiv env polypeptides
CA2360347C (en) 1998-12-31 2013-05-07 Chiron Corporation Improved expression of hiv polypeptides and production of virus-like particles
EP1144014B1 (en) * 1999-01-28 2005-07-27 Stichting Biomedical Primate Research Center Composition and method for obtaining specific immunisation against one or more antigens using different recombinant vectors
DE19907485B4 (de) * 1999-02-12 2008-01-17 Strathmann Ag & Co. Virus-Vakzine
US6420545B1 (en) * 1999-05-24 2002-07-16 The Trustees Of The University Of Pennsylvania CD4-independent HIV envelope proteins as vaccines and therapeutics
AU3793701A (en) * 1999-11-29 2001-06-04 Orchid Biosciences, Inc. Methods of identifying optimal drug combinations and compositions thereof
US8623379B2 (en) * 2000-03-02 2014-01-07 Emory University Compositions and methods for generating an immune response
US20040105871A1 (en) * 2000-03-02 2004-06-03 Robinson Harriet L. Compositions and methods for generating an immune response
EP2388015A1 (en) 2000-03-02 2011-11-23 Emory University DNA expression vectors and methods of use
WO2002072754A2 (en) * 2001-03-08 2002-09-19 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Mva expressing modified hiv envelope, gag, and pol genes
CA2417240A1 (en) * 2000-08-07 2002-02-14 Sloan-Kettering Institute For Cancer Research Method and composition for immunization using mixed pools of mutated nucleic acids or peptides
JP2005502591A (ja) * 2001-01-12 2005-01-27 カイロン コーポレイション 核酸粘膜免疫
EP2412242A3 (en) 2001-07-05 2012-06-13 Novartis Vaccines and Diagnostics, Inc. Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof
WO2003004657A1 (en) * 2001-07-05 2003-01-16 Chiron Corporation Polynucleotides encoding antigenic hiv type b and/or type c polypeptides, polypeptides and uses thereof
GB0118532D0 (en) * 2001-07-30 2001-09-19 Isis Innovation Materials and methods relating to improved vaccination strategies
CA2458995C (en) * 2001-08-31 2013-04-30 Chiron Corporation Polynucleotides encoding antigenic hiv type b polypeptides, polypeptides and uses thereof
US20030170614A1 (en) * 2001-08-31 2003-09-11 Megede Jan Zur Polynucleotides encoding antigenic HIV type B polypeptides, polypeptides and uses thereof
US20030228327A1 (en) * 2001-11-05 2003-12-11 Lasher Alfred W. DNA-based plasmid formulations and vaccines and prophylactics containing the same
US20070269456A1 (en) * 2001-11-05 2007-11-22 Lasher Alfred W DNA-based plasmid formulations and vaccines and prophylactics containing the same
EP1450854A2 (en) 2001-11-30 2004-09-01 Isis Innovation Limited Vaccine
US7094410B2 (en) * 2002-03-02 2006-08-22 The Scripps Research Institute DNA vaccine against proliferating endothelial cells and methods of use thereof
US6923958B2 (en) * 2002-03-02 2005-08-02 The Scripps Research Institute DNA vaccines encoding CEA and a CD40 ligand and methods of use thereof
US20040106566A1 (en) * 2002-05-17 2004-06-03 Shi-Lung Lin RNA-splicing and processing-directed gene silencing and the relative applications thereof
EP2316479B8 (en) * 2002-07-18 2015-03-18 University of Washington Pharmaceutical compositions comprising immunologically active herpes simplex virus (HSV) protein fragments
WO2004050856A2 (en) * 2002-12-03 2004-06-17 University Of Massachusetts Polyvalent, primary hiv-1 glycoprotein dna vaccines and vaccination methods
US7658927B2 (en) * 2003-05-12 2010-02-09 University Of Florida Research Foundation, Inc. Materials and methods for immunizing against FIV infection
WO2004100985A2 (en) 2003-05-12 2004-11-25 University Of Florida Research Foundation, Inc. Materials and methods for immunizing against fiv infection
US8076060B2 (en) * 2003-08-04 2011-12-13 Emil William Chynn Vaccination and immunotherapy as new therapeutic modalities in the treatment of glaucoma
EP2055316A1 (en) * 2003-09-09 2009-05-06 VIRxSYS Corporation Lentivirus vector-based approaches for generating an immune response to HIV in humans
WO2005027840A2 (en) * 2003-09-15 2005-03-31 Chiron Corporation Combination approaches for generating immune responses
AU2004279362B2 (en) * 2003-09-15 2011-03-17 Genvec, Inc. HIV vaccines based on ENV of multiple clades of HIV
US20050175627A1 (en) * 2003-09-24 2005-08-11 Oxxon Therapeutics Ltd. HIV pharmaccines
US7622125B2 (en) 2004-05-05 2009-11-24 Novartis Vaccines And Diagnostics, Inc. Polycistronic HIV vector constructs
US7342107B2 (en) * 2004-05-27 2008-03-11 Centocor, Inc. Cynomolgus prostate specific antigen
WO2006101503A2 (en) * 2004-06-15 2006-09-28 Centocor, Inc. Method for screening agents against human prostate disease
CA2573702C (en) * 2004-07-16 2013-10-15 The Government Of The United States Of America As Represented By The Sec Retary Of The Department Of Health And Human Services Vaccine constructs and combination of vaccines designed to improve the breadth of the immune response to diverse strains and clades of hiv
WO2006044864A2 (en) * 2004-10-19 2006-04-27 Duke University Vaccine adjuvant
CN101072585A (zh) 2004-11-01 2007-11-14 诺华疫苗和诊断公司 产生免疫应答的组合方法
EP1828390B1 (en) * 2004-12-15 2012-06-13 The University Of North Carolina At Chapel Hill Chimeric vectors
WO2008048984A2 (en) * 2006-10-18 2008-04-24 St. Jude Children's Research Hospital Methods and compositions for preparing a universal influenza vaccine
EP2396343B1 (en) 2009-02-11 2017-05-17 The University of North Carolina At Chapel Hill Modified virus vectors and methods of making and using the same
EA025417B1 (ru) * 2010-11-22 2016-12-30 Борис Славинович ФАРБЕР Вакцины с повышенной иммуногенностью и способы их получения
EP2670434B1 (en) 2011-01-31 2018-12-26 Tau Bio-Logic Corp. Treatment of tauopathies
EP3173096A1 (en) 2011-04-06 2017-05-31 Biovaxim Limited Pharmaceutical compositions for preventing and/or treating an hiv disease in humans
WO2013074696A1 (en) 2011-11-14 2013-05-23 Novartis Ag Immunogenic complexes of polyanionic carbomers and env polypeptides and methods of manufacture and use thereof
US9833503B2 (en) 2012-02-24 2017-12-05 President And Fellows Of Harvard College Methods for displaying polypeptides and uses thereof
RS62360B1 (sr) * 2015-12-15 2021-10-29 Janssen Vaccines & Prevention Bv Antigeni, vektori i sastavi virusa humane imunodeficijencije, i postupci njihove primene
CN113874078B (zh) 2019-04-05 2025-05-06 Tauc3生物制品有限公司 抗tauc3抗体及其应用
IT202100000569A1 (it) * 2021-01-14 2022-07-14 Evobiotech S R L Composizione comprendente vescicole extracellulari vegetali ingegnerizzate e suo impiego come vaccino

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5198214A (en) * 1983-08-31 1993-03-30 Stolle Research & Development Corporation Anti-mastitis polyvalent vaccine, method of administration and method for production thereof
GR862412B (en) * 1985-09-25 1987-01-23 Oncogen Vaccines and immuinoassays for acquired immune deficiency syndrome
US5169763A (en) * 1986-04-08 1992-12-08 Transgene S.A., Institut Pasteur Viral vector coding glycoprotein of HIV-1
IL82104A0 (en) * 1986-04-08 1987-10-30 Usa Recombinant vaccinia virus expressing human retrovirus genes and method for producing htlb-iii envelope proteins
US5081226A (en) * 1986-12-30 1992-01-14 The United States Of America As Represented By The Department Of Health And Human Services Synthetic peptides sharing sequence homology with the HIV envelope protein
ATE160377T1 (de) * 1989-04-18 1997-12-15 Applied Biotechnology Inc Erzeugung von hybrid-genen und proteinen durch rekombination mittels viren
AU672581B2 (en) * 1991-03-07 1996-10-10 Virogenetics Corporation Immunodeficiency virus recombinant poxvirus vaccine
US5643578A (en) * 1992-03-23 1997-07-01 University Of Massachusetts Medical Center Immunization by inoculation of DNA transcription unit
DE69536091D1 (de) * 1994-01-27 2010-09-09 Univ Massachusetts Medical Immunisierung durch Impfung von DNS Transkriptionseinheit
FR2728794B1 (fr) * 1994-12-30 1997-03-21 Rhone Merieux Vaccin recombinant aviaire a base de virus herpes aviaire, notamment contre la maladie de gumboro

Also Published As

Publication number Publication date
KR100571479B1 (ko) 2007-06-07
PL188641B1 (pl) 2005-03-31
CA2243570C (en) 2001-08-14
EP0876498B1 (en) 2004-10-06
BR9707611A (pt) 1999-07-27
NO983377D0 (no) 1998-07-22
AP9801325A0 (en) 1998-09-30
JP2000504326A (ja) 2000-04-11
EA199800638A1 (ru) 1999-02-25
DK0876498T3 (da) 2005-02-07
GEP20032902B (en) 2003-02-25
HK1016218A1 (en) 1999-10-29
CN1229501C (zh) 2005-11-30
RO120268B1 (ro) 2005-11-30
BG64711B1 (bg) 2005-12-30
DE69731075T2 (de) 2006-03-09
KR19990081931A (ko) 1999-11-15
NO322261B1 (no) 2006-09-04
CZ229398A3 (cs) 1998-12-16
PL328193A1 (en) 1999-01-18
WO1997027311A1 (en) 1997-07-31
UA73712C2 (en) 2005-09-15
OA10814A (en) 2003-01-28
CA2243570A1 (en) 1997-07-31
NO983377L (no) 1998-09-23
PT876498E (pt) 2005-02-28
EA002390B1 (ru) 2002-04-25
AU709174B2 (en) 1999-08-26
IL125497A0 (en) 1999-03-12
HUP9900389A2 (hu) 1999-06-28
DE69731075D1 (de) 2004-11-11
US5846546A (en) 1998-12-08
HUP9900389A3 (en) 2001-06-28
HU0402182D0 (en) 2004-12-28
NZ331024A (en) 2000-02-28
JP2007259870A (ja) 2007-10-11
EP0876498A1 (en) 1998-11-11
CN1214083A (zh) 1999-04-14
EP1378516A1 (en) 2004-01-07
IL156919A0 (en) 2004-02-08
US5741492A (en) 1998-04-21
ES2230596T3 (es) 2005-05-01
ATE278790T1 (de) 2004-10-15
IL125497A (en) 2007-07-04
CZ296575B6 (cs) 2006-04-12
AP1200A (en) 2003-08-29
US6086891A (en) 2000-07-11
BG102712A (en) 1999-04-30
HU224344B1 (hu) 2005-08-29
AU1829997A (en) 1997-08-20

Similar Documents

Publication Publication Date Title
TR199801418T2 (xx) Rekombinant a�� vekt�rleri kar���m�.
ATE315667T1 (de) Amplifizierung und detektion von hiv-1 und/oder hiv-2
DK0760848T3 (da) Lactobacillusstammer af menneskelig oprindelse, deres sammensætninger og anvendelse deraf
CY1107393T1 (el) Τροποποιημενα env πολυπεπτιδια του hiv
FR2731013B1 (fr) Vih-1 de groupe o, fragments desdits virus, ainsi que leurs applications
DE60023300D1 (de) Verwendung von cpg als adjuvans für hivimpstoff
ZA964694B (en) Recombinant raccoon pox viruses and their use as an effective vaccine against feline immunodeficiency virus infection.
ATE264914T1 (de) Antivirale proteine, dafür kodierende dna, und deren verwendung
ATE59845T1 (de) Pflanzenschuetzende mittel auf basis von 1,2,4triazolderivaten sowie neue derivate des 1,2,4triazols.
HUP0002224A1 (hu) Virusellenes hatású benzimidazol-származékok
FI953717L (fi) 4-Hydroksibentsopyran-2-oneja ja 4-hydroksisykloalkyyli(b)pyran-2-oneja, joita voidaan käyttää retrovirusinfektioiden hoitamiseen
EE9700201A (et) Aminohappe hüdroksüetüülamino-sulfoonamiidsed retroviirusliku proteaasi inhibiitorid
PT1052250E (pt) Inibidores de protease retroviral sulfonilalcanoilamino hidroxietilamino sulfonamidas
TR200002921T2 (tr) Yarı-Sentetik ekteinasidinler
DK0767172T3 (da) 8-arylalkyl- og 8-arylheteroalkyl-5,11-dihydro-6H-dipyrido[3,2-b:2',3'-e][1,4]diazepiner og deres anvendelse til forebyggelse eller behandling af HIV-infektion
PT1169057E (pt) Vacina anti-hiv-1 compreendendo o todo ou parte de uma proteina tat de vih-1
HUP9901035A2 (hu) Idegen DNS-t tartalmazó parapoxvírusok, előállításuk és alkalmazásuk vakcinákban
TR199802704T2 (xx) H�V tedavisinde Vx478, Zidov�din, FTC ve/veya 3TC i�eren kombinasyonlar�n kullan�m�.
BR0211186A (pt) peptìdeos e uso dos mesmos no escurecimento da pele
ZA964679B (en) Genetically altered feline immunodeficiency viruses and their use as an effective vaccine against feline immunodeficiency virus infection.
EP1036165A4 (en) HUMAN RNASE-H AND COMPOSITIONS AND USES THEREOF
DE69124215D1 (de) Primaten-lentivirus impfstoffe
ATE308306T1 (de) Verwendung von wasserunlöslichen linearen poly- alpha-glucan als uv-filter
BR9801143A (pt) Copolìmeros de bloco de siloxano inovativos com espaçamento rìgidos e uso dos mesmos.
ATE189460T1 (de) Gegen protozoen wirksamezyklische tetrapeptide